Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data
- 30 November 2007
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 8 (11), 994-1000
- https://doi.org/10.1016/s1470-2045(07)70284-x
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancerAnnals of Oncology, 2007
- Hoosier Oncology Group Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival AnalysisClinical Cancer Research, 2006
- Multi-Institutional Randomized Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) With or Without Estramustine Phosphate in Patients With Progressive Castrate Metastatic Prostate CancerJournal of Clinical Oncology, 2005
- Thromboembolic events with estramustine phosphate‐based chemotherapy in patients with hormone‐refractory prostate carcinomaCancer, 2004
- Chemotherapy for patients with hormone-refractory prostate cancerAnnals of Oncology, 2004
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerNew England Journal of Medicine, 2004
- Meta-analyses of randomised clinical trials in oncologyThe Lancet Oncology, 2001
- Interaction of Estramustine with Tubulin IsotypesBiochemistry, 1997
- Preclinical and clinical perspectives on the use of estramustine as an antimitotic drugPharmacology & Therapeutics, 1992
- Meta-Analyses of Randomized Controlled TrialsNew England Journal of Medicine, 1987